The impact of EGFR mutation on definitive concurrent chemoradiation therapy for inoperable stage III lung adenocarcinoma.

Abstract

7558 Background: Concurrent chemoradiation therapy (CRT) is the current standard of care for patients with locally advanced lung adenocarcinoma, however little has been reported about the impact of EGFR mutation to CRT efficacy. Methods: From 2005-2012, we retrospectively screened 73 unresectable stage III adenocarcinoma patients who were examined EGFR mutation status and received definitive concurrent CRT consisting of platinum doublet in first-line setting, and compared the clinical outcomes and recurrence patterns according to mutation status. Results: Among 73 patients, EGFR mutation was detected in 21 (28.8%). Overall response rate did not differ between EGFR-mutant and wild-type patients (66.7% vs. 74.0%, p=0.362). Median recurrence-free survival (RFS) in concurrent CRT was significantly shorter in EGFR-mutated patients than wild-type patients (8.7 [95%CI: 6.7-10.8] vs. 13.5 [95%CI: 11.0-18.3] months, p=0.022). The 2 year recurrence-free survival rate was 5.6% and 23.8% in EGFR-mutant and wild-type ...